Suppr超能文献

垂体腺瘤的术后放射治疗。

Postoperative radiation therapy for pituitary adenoma.

作者信息

Isobe K, Ohta M, Yasuda' S, Uno T, Hara R, Machida N, Saeki N, Yamaura A, Shigematsu N, Ito H

机构信息

Department of Radiology, Chiba University, School of Medicine, Japan.

出版信息

J Neurooncol. 2000 Jun;48(2):135-40. doi: 10.1023/a:1006477905230.

Abstract

BACKGROUND

We evaluated the efficacy of postoperative radiation therapy (RT), prognostic factors for local control probability, dose response relationship and treatment sequelae in 75 patients with pituitary adenoma.

MATERIALS AND METHODS

A total dose of 48-60 Gy (median: 50 Gy) was delivered with a conventional fractionation schedule after surgery. Of 75 patients, 55 (73%) were followed for more than 5 years and 27 (36%) were followed for more than 10 years with a median of 95 months.

RESULTS

Five- and 10-year local control probabilities were 87.1% and 85.0%, respectively. Univariate analysis revealed that age (p = 0.007), tumor volume smaller than 30 cm3 (p = 0.018) and the absence of prolactin secretion (p = 0.003) were significantly favorable prognostic factors for local control probability. After multivariate analysis combining these 3 factors, tumor volume smaller than 30 cm3 (p = 0.017) and age (p = 0.039) were statistically significant. Patients with prolactinoma greater than 30 cm3 showed particularly poor local control rates. No significant improvement of the local control rate was detected with increasing total irradiation doses between 48 and 60 Gy (p = 0.29). The most common side effect was hypopituitarism, and there were no severe sequelae such as optic neuropathy or brain necrosis.

CONCLUSION

Except with prolactinoma, the dose of postoperative RT for pituitary adenoma should not exceed 50 Gy. Large prolactinoma, however, was very difficult to control with the irradiation doses between 50 and 60 Gy, and would be good candidates for stereotactic radiosurgery or stereotactic radiation therapy.

摘要

背景

我们评估了75例垂体腺瘤患者术后放射治疗(RT)的疗效、局部控制概率的预后因素、剂量反应关系及治疗后遗症。

材料与方法

术后采用常规分割方案给予总剂量48 - 60 Gy(中位剂量:50 Gy)。75例患者中,55例(73%)随访超过5年,27例(36%)随访超过10年,中位随访时间为95个月。

结果

5年和10年局部控制概率分别为87.1%和85.0%。单因素分析显示,年龄(p = 0.007)、肿瘤体积小于30 cm³(p = 0.018)以及无催乳素分泌(p = 0.003)是局部控制概率的显著有利预后因素。将这3个因素进行多因素分析后,肿瘤体积小于30 cm³(p = 0.017)和年龄(p = 0.039)具有统计学意义。肿瘤体积大于30 cm³的催乳素瘤患者局部控制率特别低。在48至60 Gy之间增加总照射剂量未发现局部控制率有显著提高(p = 0.29)。最常见副作用是垂体功能减退,未出现视神经病变或脑坏死等严重后遗症。

结论

除催乳素瘤外,垂体腺瘤术后放疗剂量不应超过50 Gy。然而,大体积催乳素瘤在50至60 Gy的照射剂量下很难控制,可能是立体定向放射外科或立体定向放射治疗的良好候选者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验